Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Privia Health Group’s fair value estimate has been fine tuned to US$31.95 from US$31.85, keeping the modeled price target firmly in the low US$30s range. That small adjustment sits within a broader set of Street targets clustered around the low to mid US$30s, reflecting a mix of constructive views on recent Q4 results and more cautious takes around valuation and claims timing. As you read on, you will see how these shifting targets fit into the evolving analyst narrative and how to track it over time.
JPMorgan lifted its price target to US$35 from US$33 after what it called a solid Q4 report and adjusted its estimates accordingly, signaling confidence in execution following recent results.
Jefferies raised its target to US$32 from US$30 after an “impressive” Q4 beat and pointed to ongoing momentum and recent acquisitions as supports for its positive view.
Truist increased its target to US$33 from US$31, citing management commentary that averaging Q3 and Q4 gives a clearer picture of second half performance and highlighting context around fee for service Practice Collections and claims timing.
RBC Capital resumed coverage with an Outperform rating and a US$31 target, framing Privia as a key player in physician enablement with a payor agnostic model and an expanding physician network and fee based collections.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqGS:PRVA 1-Year Stock Price Chart
We’ve flagged 1 risk for Privia Health Group. See which could impact your investment.
Privia Health, Amalgam Rx, and Exact Sciences reported a colorectal cancer screening rate of 84% in 2024 using EHR integrated workflows and automated outreach, above national benchmarks and the National Colorectal Cancer Roundtable’s 80% goal.
The colorectal cancer screening program initially reached more than 42,000 patients across two markets and was later scaled to over 100,000 patients nationally, with about 23,000 screening orders processed within 48 hours and limited staff involvement.
Program data showed a 10% positivity rate, identified more than 550 patients needing diagnostic follow up, and led to 37% of patients booking doctor appointments after outreach, which supports value based care and quality measurement efforts.
Privia Health issued fiscal 2026 earnings guidance, targeting GAAP revenue in the range of US$2.35b to US$2.45b.
Story Continues
Fair value updated to US$31.95 from US$31.85, remaining in the low US$30s range.
Revenue growth assumption maintained at about 11.45%, with only a minimal refinement.
Net profit margin kept essentially unchanged at about 3.09% in the model.
Future P/E ratio adjusted marginally to 55.54x from 55.37x.
Discount rate held effectively steady at 6.98% with no material change in the risk assumption.
Narratives link a company’s real world story to the assumptions behind its forecasts and fair value estimates. They update as new research, guidance, and risks emerge so you can see what has changed and why.
Head over to the Simply Wall St Community and follow the Narrative on Privia Health Group to stay up to date on:
How aging U.S. demographics, value based care adoption, and new market entries are feeding into expectations for Privia Health Group’s future revenue and earnings.
The role of proprietary technology, AI driven workflow automation, and a diversified contract mix across commercial, Medicare, and Medicaid in supporting EBITDA and margin assumptions.
Key risks around industry consolidation, regulatory change, labor costs, technology competition, and execution on provider network expansion that could challenge this narrative over time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PRVA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com